scholarly article | Q13442814 |
P356 | DOI | 10.1097/INF.0000000000000240 |
P698 | PubMed publication ID | 24356256 |
P50 | author | Xavier Sáez-Llorens | Q68327803 |
P2093 | author name string | Octavio Ramilo | |
Genevieve A Losonsky | |||
M Pamela Griffin | |||
Rosanna Lagos | |||
JoAnn Suzich | |||
Kathryn M Jensen | |||
C Kathy Wang | |||
Brian S Harris | |||
Motavizumab Study Group | |||
P433 | issue | 7 | |
P407 | language of work or name | English | Q1860 |
P921 | main subject | viral load | Q2528140 |
hospitalization | Q3140971 | ||
P304 | page(s) | 703-709 | |
P577 | publication date | 2014-07-01 | |
P1433 | published in | Pediatric Infectious Disease Journal | Q15756717 |
P1476 | title | Motavizumab treatment of infants hospitalized with respiratory syncytial virus infection does not decrease viral load or severity of illness | |
P478 | volume | 33 |
Q59352372 | A Nonhospitable Host: Targeting Cellular Factors as an Antiviral Strategy for Respiratory Viruses |
Q40823850 | A Recombinant G Protein Plus Cyclosporine A-Based Respiratory Syncytial Virus Vaccine Elicits Humoral and Regulatory T Cell Responses against Infection without Vaccine-Enhanced Disease |
Q40852832 | Adult patients with respiratory syncytial virus infection: impact of solid organ and hematopoietic stem cell transplantation on outcomes |
Q35893983 | An anti-G protein monoclonal antibody treats RSV disease more effectively than an anti-F monoclonal antibody in BALB/c mice |
Q92021897 | Antibody development for preventing the human respiratory syncytial virus pathology |
Q36994087 | Antibody therapeutics for Ebola virus disease |
Q30391416 | Antivirals for Respiratory Viral Infections: Problems and Prospects |
Q30300567 | Challenges and opportunities in developing respiratory syncytial virus therapeutics |
Q39038875 | Compassionate use experience with high-titer respiratory syncytical virus (RSV) immunoglobulin in RSV-infected immunocompromised persons |
Q38969434 | Development and clinical applications of novel antibodies for prevention and treatment of respiratory syncytial virus infection |
Q47392075 | Discharge Criteria for Bronchiolitis: An Unmet Need |
Q36438987 | Generation and Characterization of ALX-0171, a Potent Novel Therapeutic Nanobody for the Treatment of Respiratory Syncytial Virus Infection |
Q36965855 | How I treat respiratory viral infections in the setting of intensive chemotherapy or hematopoietic cell transplantation |
Q37729137 | Immunological Features of Respiratory Syncytial Virus-Caused Pneumonia-Implications for Vaccine Design |
Q38594067 | Lower respiratory tract infection caused by respiratory syncytial virus: current management and new therapeutics |
Q47886776 | Meeting report: 4th ISIRV antiviral group conference: Novel antiviral therapies for influenza and other respiratory viruses |
Q38628928 | New Insights Contributing to the Development of Effective Vaccines and Therapies to Reduce the Pathology Caused by hRSV. |
Q38604787 | Novel therapies and vaccines against the human respiratory syncytial virus. |
Q30368680 | Overview of the 3rd isirv-Antiviral Group Conference--advances in clinical management |
Q50262223 | Past, Present and Future Approaches to the Prevention and Treatment of Respiratory Syncytial Virus Infection in Children |
Q37651813 | Potent single-domain antibodies that arrest respiratory syncytial virus fusion protein in its prefusion state. |
Q92025172 | Pre-existing neutralizing antibodies prevent CD8 T cell-mediated immunopathology following respiratory syncytial virus infection |
Q34542687 | Protection and mechanism of action of a novel human respiratory syncytial virus vaccine candidate based on the extracellular domain of small hydrophobic protein |
Q38742141 | Recent Advances in Developing Antiviral Therapies for Respiratory Syncytial Virus |
Q30657338 | Redesigned HIV antibodies exhibit enhanced neutralizing potency and breadth |
Q35761061 | Respiratory syncytial virus, an ongoing medical dilemma: an expert commentary on respiratory syncytial virus prophylactic and therapeutic pharmaceuticals currently in clinical trials |
Q26796151 | Respiratory virus modulation of host nucleocytoplasmic transport; target for therapeutic intervention? |
Q47548690 | Safety, Tolerability, and Pharmacokinetics of MEDI8897, an Extended Half-Life Single-Dose Respiratory Syncytial Virus Prefusion F-Targeting Monoclonal Antibody Administered as a Single Dose to Healthy Preterm Infants |
Q49997190 | Surface-Matrix Screening Identifies Semi-specific Interactions that Improve Potency of a Near Pan-reactive HIV-1-Neutralizing Antibody |
Q41921750 | The antiviral effects of RSV fusion inhibitor, MDT-637, on clinical isolates, versus its achievable concentrations in the human respiratory tract and comparison to ribavirin. |
Q28071857 | Viral Infection in the Development and Progression of Pediatric Acute Respiratory Distress Syndrome |
Q52652828 | Virus-specific aNtibody, Viral Load and Disease Severity in Respiratory Syncytial Virus Infection. |
Q91911845 | [Community-acquired pneumonia: Focus on viral CAP] |
Search more.